fda warning letter compounding semaglutide news Beyond the Headlines: Letters to GLP-1 Compounders The Risks of Compounded Semaglutide

Larsen also noted that Marty Makary, M.D., President Donald Trump's pick to lead the FDA, will have "influence over the enforcement of semaglutide compounding and personalization efforts." Makary is an executive at Sesame, another telehealth company that connects consumers with physicians to prescribe compounded weight loss drugs

So the practitioner is the safeguard

you are getting a managed system of care

This innovative, patent-pending system is clinically shown to naturally increase GLP-1 by an average of 140% as it balances hunger hormonesno injections or prescriptions required

"Many times obesity treatment is framed as a limited duration intervention that once people get to a weight goal or percentage of weight reduction, that then treatment can be discontinued," Almandoz says

PlexusDx focuses on precision-guided treatment options and biomarker insights to help personalize your approach